title: Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression.
abstract: The expression of the erbB2 and p53 proteins was examined by immunohistochemistry in a series of 81 cases of primary breast carcinomas treated with an adjuvant chemotherapy with a median follow-up of 5 years. Expression of erbB2 was present in 19 cases (23%), 50% of them with more than 70% of positive tumoral cells. Expression of p53 was present in 32 cases (39%), 50% of them with more than 30% of positive tumoral cells; coexpression of erbB2 and p53 was observed in 11 cases (13.5%). Disease-free and overall survival of the patients were correlated with the number of positive lymph nodes (p = 0.08, p = 0.015). No significant trend was observed in response to adjuvant chemotherapy in correlation with erbB2 or p53 expression or both, whatever the level of expression.
authors.affiliation: Department d'Anatomie Pathologique, Institut Paoli-Calmettes, Marseille, France.
authors.forename: J
authors.initials: J
authors.lastname: Jacquemier
authors.forename: F
authors.initials: F
authors.lastname: Penault-Llorca
authors.forename: P
authors.initials: P
authors.lastname: Viens
authors.forename: G
authors.initials: G
authors.lastname: Houvenaeghel
authors.forename: J
authors.initials: J
authors.lastname: Hassoun
authors.forename: M
authors.initials: M
authors.lastname: Torrente
authors.forename: J
authors.initials: J
authors.lastname: Adélaïde
authors.forename: D
authors.initials: D
authors.lastname: Birnbaum
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D015870:Gene Expression; D006801:Humans; D007150:Immunohistochemistry; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D008942:Mitoxantrone / Q000627:therapeutic use; D010052:Ovariectomy; D011237:Predictive Value of Tests; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis / Q000096:biosynthesis*; D013629:Tamoxifen / Q000627:therapeutic use; D016159:Tumor Suppressor Protein p53 / Q000032:analysis / Q000096:biosynthesis*
chemical_list: D014408:Biomarkers, Tumor; D002945:Cisplatin; D005472:Fluorouracil; D008727:Methotrexate; D008942:Mitoxantrone; D018719:Erb-b2 Receptor Tyrosine Kinases; D013629:Tamoxifen; D016159:Tumor Suppressor Protein p53